Pharmaceuticals

Kato Wins FDA Approval for Human Studies of Drug for Retinal Disorders

Resolv ER™ may remedy leading causes of blindness in adults LAGUNA HILLS, Calif., Feb. 17, 2022 /PRNewswire/ -- Kato Pharmaceuticals, a privately-held clinical stage biopharmaceutical company, today announced that the FDA has approved the company's investigational new drug (IND) application to c...

2022-02-17 12:14 3419

CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) and RET-Altered Thyroid Cancers in Taiwan, China

SUZHOU, China, Feb. 17, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the Taiwan Food and Drug A...

2022-02-17 09:19 5390

Innovent Announces Two Registration Studies of IBI306 (anti-PCSK-9 antibody) Met Primary Endpoint

SAN FRANCISCO and SUZHOU, China, Feb. 17, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major dise...

2022-02-17 08:00 5611

BIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein

SUGGESTS superior cardiAC safety compared to mRNA AND ADENOVIRUS VECTOR vaccines VANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAX) ("BioVaxys" or "Company") announced today that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protei...

2022-02-16 21:00 6151

JIXING ANNOUNCES RECEIPT OF BREAKTHROUGH THERAPY DESIGNATION FOR AFICAMTEN IN CHINA

SHANGHAI, Feb. 16, 2022 /PRNewswire/ -- Ji Xing Pharmaceuticals Limited (JIXING), a clinical-stage biopharmaceutical company committed to bringing innovative medicines to underserved Chinese patients with serious and life-threatening diseases, today announced that the Center for Drug Evaluation ...

2022-02-16 18:06 4229

Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)

HONG KONG, Feb. 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or " Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that they have received the "safe to proceed" letter from the U.S. Food and Drug Adminis...

2022-02-16 17:04 4561

NIBIOHN, Shionogi Discover Host Immune-dependent Novel Anti-coronavirus Antibody

OSAKA, Japan, Feb. 16, 2022 /PRNewswire/ -- The National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN;Ibaraki-shi, Osaka; Director-general:Yoshihiro Yoneda), in partnership with Shionogi & Co., Ltd. (Chuo-ku,Osaka; President and CEO: Isao Teshirogi), has successfully identif...

2022-02-16 14:00 3738

A Breakthrough in Probiotic Therapy - Personalized Probiotics (Dispensing) Machine for a Balanced and Enhanced Immune System

BANGKOK, Feb. 16, 2022 /PRNewswire/ -- MED-CU has invented a Personalized Probiotics (Dispensing) Machine to deliver live microorganisms that have health benefits to treat patients with unclear health problems and those with microbial imbalances or "dysbiosis".

2022-02-16 10:00 3014

Travecta Therapeutics Appoints Leading Experts to Expand its Scientific Advisory Leadership Team

PRINCETON, N.J. and SINGAPORE, Feb. 15, 2022 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced significant expansion of the Scientific Advisory B...

2022-02-15 21:00 2549

HPG: New Breakthrough in Virus Inactivation with Green Tea Catechin (EGCg)

TOKYO, Feb. 15, 2022  /PRNewswire/ -- HPG Co., Ltd. (Chuo-ku, Tokyo) has successfully developed a water-soluble formulation technology of highly concentrated catechin EGCg (Epigallocatechin gallate) with excellent storage stability and initiated procedures for a patent application for the technol...

2022-02-15 16:00 4233

G-NiiB probiotics - world's first microbiome-based immunity formulas now available at IMI

HONG KONG, Feb. 15, 2022 /PRNewswire/ -- IMI - Integrated Medicine Institute, Asia's largest natural health clinic, is pleased to announce the availability of G-NiiB Immunity Proand G-NiiB Immunity Plus probiotic formulas designed to tackle gut bacterial imbalances (dysbiosis) - a widespread healt...

2022-02-15 09:30 4256

Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients

HANGZHOU, China and SHAOXING, China, Feb. 14, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that Shanghai Public Health Clinical Center initiated functional cure study of anti-PD-L1 antibody ASC22 (Envafolimab) in combination with Chidamide in patients infected by human ...

2022-02-14 17:34 4795

U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio

SAN FRANCISCO and SUZHOU, China, Feb. 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...

2022-02-14 08:00 5132

Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Multiple European Countries

HANGZHOU, China and SHAOXING, China, Feb. 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that it has submitted marketing authorization applications for ritonavir (100 mg film-coated tablet) inGermany, France, Ireland and United Kingdom through its agent in Europe. It i...

2022-02-13 18:30 5348

Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial

- PREVENT-19 pediatric expansion in adolescents aged 12 through 17 achieved primary effectiveness endpoint demonstrating comparability to adult population - Trial demonstrated 82% clinical efficacy against Delta variant - Immune responses were about two-to-three-fold higher in adolescents than in...

2022-02-11 10:45 5036

FDA Advisory Committee Votes to Recommend Additional Data for Sintilimab Submission

SAN FRANCISCO, and SUZHOU, China, Feb. 11, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) held a public Oncology Drug Advisory Committee (ODAC) for sintilimab, which is under review for the first-line treatment of people with non-squamous non-small cell lung cancer (nsqNSCLC) ba...

2022-02-11 10:44 4993

Alphamab Oncology Announced IND Approval of PD-L1/OX40 Bispecific Antibody KN052

SUZHOU, China, Feb. 11, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, that the company received the IND approval from the National Medical Products Administration (NMPA) for the company's innovative bispecific antibody KN052 (PD-L1/OX40 bispecific antibody) to initiate c...

2022-02-11 09:31 4675

Seegene Signs Supply Deal to Deliver 4 million COVID-19 Tests to Brazil

SEOUL, South Korea, Feb. 10, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostic company, today announced that it has signed a supply deal with the Ministry of Health ofBrazil to deliver four million COVID-19 tests. Since January 2022, Brazil has battled a...

2022-02-10 20:00 3081

GenScript Sets Up State-Of-Art Manufacturing Facility in Singapore to Strengthen Manufacturing Capability

SINGAPORE, Feb. 10, 2022 /PRNewswire/ -- GenScript Biotech Corporation (Stock Code: 1548.HK), the world's leading life science research tools and services provider, today announced the opening of more than 30,000-square-feet facility for highly automated protein and gene preparation services. The...

2022-02-10 16:34 9359

TABERNACLE HEALTH GROUP LAUNCHES CHINESE PROPRIETARY MEDICINE, AVROCIL (TM) COLD AND FLU AID

SINGAPORE, Feb. 10, 2022 /PRNewswire/ -- As we enter the cold and flu season, it can be cumbersome to fall sick when the rest of the world is celebrating the New Year. Avrocil™ – Cold & Flu Aid (Product Photos) For those who hav...

2022-02-10 15:17 3891
1 ... 161162163164165166167 ... 184